Randomized Trial Comparing Colesevelam vs. Ezetimibe

Summary

A 24-week, randomized, open-label study investigating the efficacy, safety and tolerability of colesevelam 3.75 g daily compared to ezetimibe 10 mg daily, as an add-on to baseline statin therapy in patients with type 2 diabetes mellitus (T2DM) who are not at target for glycated hemoglobin (HbA1c) (\> 7.0%) and low-density lipoprotein (LDL) cholesterol (\> 2.0 mmol/L).

Timeline

Start

2016-01-11

Primary completion

2017-05-25

Completion

2017-05-25

Drugs

Indications